SiRNA for inhibiting IL-17A gene expression and application thereof

By designing and modifying IL-17A specific siRNA, the problems of poor efficacy and major side effects of existing IL-17 inhibitors are solved, safe and effective treatment of psoriasis is achieved, and a new biomedical treatment method is provided. , has low frequency of medication and high efficacy.

CN118910052APending Publication Date: 2024-11-08YIMEICHENGJIAN (SHANGHAI) BIOMEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411085842.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing IL-17 inhibitors have problems such as having great side effects, poor efficacy and inability to completely inhibit IL-17 when treating psoriasis. In addition, traditional drugs have a long development cycle, high immunogenicity and high medication frequency, which makes it difficult to meet the psoriasis. treatment needs.

Method used

A siRNA that inhibits the expression of IL-17A gene is designed to enhance its stability in serum and knockdown effect in cells through specific sequence and chemical modification, and is administered using skin medication to provide a safe , effective treatment methods.

Benefits of technology

实现了对IL-17A的特异性降低,减少相关炎症因子的表达,显著改善银屑病症状,具有较低的用药频率和总费用,且通过化学修饰增强了siRNA的稳定性和疗效。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910052A_ABST
    Figure CN118910052A_ABST
Patent Text Reader

Abstract

The invention discloses siRNA (small interfering ribonucleic acid) capable of inhibiting IL-17A (interleukin-17A) gene expression and application of the siRNA. The sequence of a positive-sense strand of the siRNA is SS-5 'AGAUAUCCCUCGUGAUCGGGA-3', and the sequence of an antisense strand of the siRNA is AS-5 'UCCCAGAUCACAGAGGGAUAUCU-3'. Meanwhile, two effective chemical modification methods are designed aiming at the sequence, one method is to carry out methoxy modification on part of basic groups, and the other method is to carry out methoxy modification or fluoro modification on all basic groups, so that not only is the ability of siRNA to resist enzyme hydrolysis enhanced, but also the siRNA has a good function of knocking down a target gene, and the siRNA can be used for preparing the siRNA. And a treatment method with good safety and remarkable curative effect is provided for psoriasis and other autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a siRNA for inhibiting IL-17A gene expression and an application thereof. Background Art

[0002] Interleukin 17 (IL-17) is one of the more than 30 interleukins discovered so far. There are six family members in the IL-17 family, namely IL-17A-F. Among them, IL-17A is located on chromosome 6p12 and is an important pro-inflammatory cytokine.

[0003] The main targets involved in psoriasis are: TNF-α, IL-12, IL-23 and IL-17; among them, IL-12 and IL-23 activate the JAK-STAT signaling pathway by binding to the IL-12R receptor and IL-23R receptor respectively, and its disorder can lead to the occurrence of autoimmune diseases. IL-17 is mainly produced by T helper cells TH17, which can induce epithelial cells, endothelial cells, and fibroblasts to synthesize and secrete pro-inflammatory factors such as IL-6, IL-8, G-CSF, PGE2, activate, induce chemotaxis and maintain the stability of neutrophils, and promote the formation of new blood vessels.

[0004] The signal transduction regulation of IL-17A mainly depends on important molecules such as TRAF6, Act1, and microRNA-23b. In autoimmune diseases with high expression of IL-17A, such as psoriasis and rheumatoid arthritis, the expression of microRNA-23b decreases, which relieves the inhibition of IL-17-NF-κB, causing the IL-17A signal to be overactivated and promote inflammatory diseases and autoimmune diseases. Therefore, IL-17 inhibitors have a mitigating and therapeutic effect on the development of autoimmune diseases.

[0005] In addition, IL-17A is not only significantly associated with psoriasis, but also participates in regulating the expression of factors such as IL-6, CXCL, CCL20, IL-1β, IL-23, inducing inflammatory diseases, tumor diseases, bacterial infectious diseases, systemic lupus erythematosus, multiple sclerosis, hypertension, atherosclerosis, etc.

[0006] Clinically, TNF-α inhibitors have significant side effects, and IL-23 inhibitors cannot completely inhibit IL-17. Other IL-17s that are independent of Th17 cells can still be produced. IL-17 is a core pathogenic factor that directly participates in the production of psoriasis inflammation and disease progression, and is more directly related to the onset of psoriasis. Drugs that inhibit IL-17 are known for their rapid onset of action. Therefore, targeting IL-17 to treat psoriasis is still expected in the market.

[0007] At present, there are four monoclonal antibody drugs targeting IL-17 approved for the treatment of psoriasis, namely Secukinumab, Ixekizumab, Brodalumab and Bimekizumab. Neutralizing IL-17A (Secukinumab and Ixekizumab) or IL-17RA (Brodalumab) and IL-17A / IL-17F (Bimekizumab) through monoclonal antibodies is a very effective method for treating psoriasis. The common indications of these four antibody drugs are moderate to severe plaque psoriasis. Among them, Secukinumab and Ixekizumab are treated by subcutaneous injection. After 12 weeks, the treatment effect is better than Pfizer's etanercept (TNF-α antagonist). Taking the indication of plaque psoriasis as an example, the PASI 75 (psoriasis skin score) data of IL-17 antibody can achieve better efficacy or faster response than TNF-α, IL-23, and JAK. For example, the PASI 75 (16-week data) of the TNF-α inhibitor adalimumab is 71%, the PASI 75 (12-week data) of etanercept is 47%, and the PASI 75 (12-week data) of the JAK inhibitor tofacitinib is only 54%; in comparison, for IL-17 inhibitors, Novartis's secukinumab PASI 75 (12-week data) is 77-82%, and Eli Lilly's ixekizumab PASI 75 (12-week data) is 87-90%.

[0008] siRNA therapy is an innovative mechanism drug that acts on the upstream of proteins, regulating protein expression at the mRNA level and solving the problem that most protein targets have not yet been discovered. The mechanism of action of siRNA drugs is as follows: double-stranded siRNA molecules are assembled into RNA-induced silencing complexes (RISC) in the cytoplasm, followed by degradation of one strand (sense strand) of the siRNA, and the other strand (antisense strand) binds to the mRNA with complementary bases, thereby shearing the target mRNA to achieve the purpose of downregulating the target gene. On the one hand, compared with traditional small molecule chemical drugs and biological preparations, siRNA drugs have the advantages of short R&D cycle, high drug success rate, and long-lasting efficacy. On the other hand, siRNA drugs have the advantages of strong sequence targeting, low immunogenicity, easy amplification and production of drugs, and reduced frequency of medication (Humira is used once every two weeks, and siRNA-T1 drugs are expected to be used once every quarter). Therefore, the unique advantages of small nucleic acid drugs make it possible to open up a new development direction for the modern biopharmaceutical industry, further fill the treatment gaps of existing therapies, and have the potential to cure diseases.

[0009] The siRNA-IL17A preparation developed by the present invention is the first drug in China and abroad to use small nucleic acids for the treatment of psoriasis. The drug is mainly composed of two parts: siRNA sequence and delivery system. It is multidisciplinary and has high technical barriers. It is expected to open up new drugs for psoriasis in addition to traditional chemical drugs and biological agents, bringing more benefits to patients in terms of efficacy and convenience. Summary of the invention

[0010] In order to solve the above-mentioned deficiencies in the prior art, the present invention designs and synthesizes a siRNA that inhibits the expression of the IL-17A gene based on the sequence characteristics of the IL-17A gene, so as to specifically knock down the expression level of the IL-17A gene and reduce the expression of other inflammatory factors in the signaling pathway. At the same time, the sequence is modified to solve the stability problem of the siRNA in serum and avoid potential cytotoxicity, thereby providing a safe and effective treatment method for psoriasis and other autoimmune diseases.

[0011] The technical solution adopted by the present invention is as follows:

[0012] The first object of the present invention is to provide a siRNA for inhibiting IL-17A gene expression, wherein the sequence of the sense strand of the siRNA is SS-5'AGAUAUCCCUCUGUGAUCUGGGA-3', and the sequence of the antisense strand is AS-5'UCCCAGAUCACAGAGGGAUAUCU-3'.

[0013] Furthermore, the siRNA also includes chemical modifications to its sense strand and antisense strand.

[0014] Furthermore, the chemical modification is selected from one or both of methoxy modification and fluorine modification.

[0015] Furthermore, the chemical modification is to perform methoxy modification on the 4th, 6th to 12th, 14th and 17th to 19th bases from the 5' end of the sense strand and the 8th and 21st bases from the 5' end of the antisense strand.

[0016] Furthermore, the chemical modification is to perform methoxy modification on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st and 23rd bases from the 5' end of its sense strand and the 1st, 2nd, 4th, 6th, 8th, 10th, 12th, 14th, 16th, 18th, 20th and 22nd bases from the 5' end of its antisense strand; and to perform fluorine modification on the 2nd, 4th, 6th, 8th, 10th, 12th, 14th, 16th, 18th, 20th and 22nd bases from the 5' end of its sense strand and the 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st and 23rd bases from the 5' end of its antisense strand.

[0017] Furthermore, the structural formulas of the methoxy-modified and fluorinated bases are shown in the following formulas Ⅰ and Ⅱ, respectively:

[0018]

[0019] The second object of the present invention is to provide a use of the above siRNA in the preparation of a drug for treating psoriasis.

[0020] Furthermore, the drug is administered by skin administration.

[0021] The beneficial effects of the present invention are as follows:

[0022] 1. The present invention designs a pair of siRNA-IL17A sequences, and designs two effective chemical modification methods for the sequences. One is to perform methoxy modification on some bases, and the other is to perform methoxy modification or fluorine modification on all bases, which not only enhances the ability of siRNA to resist enzymatic hydrolysis, but also has a good function of knocking down the target gene.

[0023] 2. After comparison on NCBI, the siRNA-IL17A sequence designed by the present invention can theoretically completely target humans, rats, and mice, and is a multi-species targeting siRNA sequence with strong specificity.

[0024] 3. The siRNA drug based on the present invention has the following advantages over monoclonal antibody drugs targeting IL-17A, such as secukinumab and ixekizumab, for treating psoriasis: (1) It acts at the mRNA level, earlier than monoclonal antibody drugs acting at the protein level, with low frequency of use and low total cost; (2) It is solid-phase synthesized and has a simple source; (3) It can be combined with a delivery carrier to make a transdermal preparation for application, thereby reducing the pain felt by the patient.

[0025] 4. IL-17A is a member of the interleukin family, which is involved in a variety of immune regulation. In immune diseases and allergic diseases, the mechanism of action of IL17A is clear. Therefore, the siRNA-IL17A sequence designed and modified by the present invention is expected to provide a new treatment method for these diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 It is the sequence diagram of siRNA-IL17Amode1.

[0027] Figure 2 It is the sequence diagram of siRNA-IL17Amode2.

[0028] Figure 3 This is the electrophoresis run of unmodified siRNA-IL17A and modified siRNA-IL17Amode1~2.

[0029] Figure 4 This is a diagram showing the effect of transfection with siRNA-IL17Amode1~2 (150poml).

[0030] Figure 5 It is the change rate of body weight (vs. Day-1) of mice in each group over time.

[0031] Figure 6 This is a comparison of the skin thickness of each group of mice on Day 11.

[0032] Figure 7 is the expression level of siRNA-IL17Amode2 in epidermal cells (vs. negative group).

[0033] Figure 8 These are typical back photos of mice in each group on day 5, day 8, and day 11 of the experiment.

[0034] Fig. 9 These are HE staining images of the back skin sections of each group of mice on day 5, day 8 and day 11 of the experiment. DETAILED DESCRIPTION

[0035] The technical solution of the present invention is clearly and in detail described below in conjunction with specific embodiments. It should be understood that the following embodiments are only part of the embodiments of the present invention rather than all the embodiments, and are not intended to limit the scope of the present invention.

[0036] Example 1. Design and modification of siRNA-IL17A sequence

[0037] (1) The NCBI gene ID of human IL-17A is 3605. Using the transcript NM_002190.3 as a template, the siRNA sequence was designed while avoiding the 5' untranslated region (5'UTR), 3' untranslated region (3'UTR) and sequences near the start codon. The sequence of the sense strand was SS-5'AGAUAUCCCUCUGUGAUCUGGGA-3', and the sequence of the antisense strand was AS-5'UCCCAGAUCACAGAGGGAUAUCU-3'.

[0038] (2) Two chemical modifications were designed for the above sequence, such as Figure 1 As shown, the 4th, 6th to 12th, 14th and 17th to 19th bases from the 5' end of its sense strand and the 8th and 21st bases from the 5' end of its antisense strand were modified with methoxy groups to obtain siRNA-IL17Amode1;

[0039] like Figure 2As shown, the 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st and 23rd bases from the 5' end of its sense chain and the 1st, 2nd, 4th, 6th, 8th, 10th, 12th, 14th, 16th, 18th, 20th and 22nd bases from the 5' end of its antisense chain were modified by methoxy; the 2nd, 4th, 6th, 8th, 10th, 12th, 14th, 16th, 18th, 20th and 22nd bases from the 5' end of its sense chain and the 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st and 23rd bases from the 5' end of its antisense chain were modified by fluorine to obtain siRNA-IL17Amode2.

[0040] The structural formulas of the bases after methoxy modification and fluorine modification are shown in the following formulas Ⅰ and Ⅱ, respectively:

[0041]

[0042] Example 2: Verification of the anti-enzymatic ability of siRNA-IL17A mode 1 and mode 2 in serum

[0043] 800 ng of unmodified siRNA-IL17A, siRNA-IL17A mode1 and mode2 were taken respectively, mixed with 1 μL of fetal bovine serum, and made up to 10 μL with pure water. After being placed at 37°C for 24 h, 48 h, 72 h, and 96 h, 2% agarose gel electrophoresis was run to detect the amount of remaining siRNA. The test results are as follows: Figure 3 shown.

[0044] Depend on Figure 3 The results show that the unmodified siRNA-IL17A double-stranded had almost no detectable bands at 24h, while siRNA-IL17Amode1 and mode2 still had siRNA at 96h and the retention amount of siRNA-IL17Amode2 was higher, indicating that the modified siRNA-IL17Amode1 and mode2 had enhanced resistance to enzymatic hydrolysis, while the unmodified siRNA-IL17A had almost no ability to resist enzymatic hydrolysis.

[0045] Example 3: Verification of siRNA-IL17A mode 1 and mode 2 at the cellular mRNA level

[0046] (1) Experimental process:

[0047] ① To quantify siRNA, dilute to 20 μM with DEPC water.

[0048] ② HaCat cells were passaged to 12-well plates and the density reached about 50% before transfection the next day.

[0049] ③ During transfection, add 50pmol siRNA to 50μL DMEM medium as tube A, add 5μL lip3000 to 50μL DMEM medium as tube B, add tube A to tube B, mix well, and let stand at room temperature for 15min. Add dropwise to a 12-well plate. Set up a cell blank control group and siRNA-nc group (unmodified group) at the same time.

[0050] ④ At 48 hours, use the Tiangen kit "RNAprep Pure Cell / Bacteria Kit" (catalog number DP430) to extract the RNA genome.

[0051] ⑤Reverse transcription to obtain cDNA.

[0052] ⑥Q-PCR was used to detect the mRNA expression of IL17-A.

[0053] (2) Experimental results:

[0054] Figure 4 The figure shows the effect of HaCat cells transfected with siRNA-IL17A mode1 and mode2 (150poml). Figure 4 The results show that when siRNA-IL17Amode1150pmol was transfected, the expression was about 0.2% compared with the cell blank control group, and the expression was about 25.9% compared with the siRNA-nc group, and the knockdown effect was obvious; when siRNA-IL17Amode2150pmol was transfected, the expression was about 0.5% compared with the cell blank control group, and the expression was about 61.4% compared with the siRNA-nc group, and the knockdown effect was good.

[0055] Therefore, the siRNA-IL17A mode 1 and mode 2 designed by the present invention are suitable for the chemical modification methods of siRNA-IL17A, which not only enhance the ability of siRNA to resist enzymatic hydrolysis, but also have a good function of knocking down the target gene.

[0056] Example 4: Verification of the efficacy of siRNA-IL17A mode 2 in mice

[0057] Twelve healthy female Balb / c mice aged 8 weeks were selected, and the back hair was shaved to an area of ​​about 2cm×3cm. Then, the remaining hair was removed with a depilatory cream. From day 1, 62.5mg of 5% IMQ ointment was applied to the depilated skin on the back with a cotton swab every day for 7 days. The mice were weighed every day from day-1, and the drugs were used as planned during the period. The mice were raised for 11 days. On the 11th day, the following samples were collected: serum, skin, liver, spleen, and the thickness of the back skin was measured.

[0058] The experimental groups and medication arrangements are shown in Table 1:

[0059] Table 1

[0060]

[0061]

[0062] The experimental schedule is shown in Table 2:

[0063] Table 2

[0064]

[0065] The experimental results are as follows:

[0066] 4.1 Changes in mouse body weight

[0067] Figure 5 is the rate of change of the mouse's daily body weight compared with Day-1. Figure 5 The results show that the weight changes in the siRNA-IL17Amode2 group were similar to the overall trend of the positive control group. Although the weight loss in the siRNA-IL17Amode2 group was slightly greater than that in the positive control group, it was much smaller than that in the negative group. In the later stage of the experiment, the weight of the mice gradually recovered and showed an upward trend.

[0068] 4.2 Skin thickness

[0069] On the 11th day, the thickness of the mouse back skin was measured with an electronic vernier caliper. Figure 6 shown.

[0070] Depend on Figure 6 The results showed that the skin thickness of mice in the negative group was about 0.5 mm, which was still thickened; the skin thickness of mice in the siRNA-IL17Amode2 group was similar to that of the positive control group, and was slightly better than the positive control group. The skin thickness of mice in these three groups was about 0.4 mm, which was similar to the skin thickness of normal mice.

[0071] 4.3 Relative expression of IL-17A mRNA in skin tissue

[0072] The method of Example 3 was used to detect the expression of IL-17A mRNA in the skin tissue of mice. The RNA extraction, reverse transcription and Q-PCR methods of the skin tissue in this example were the same as those in Example 3. The detection results are shown in FIG. Figure 7 shown.

[0073] Depend on Figure 7 The results showed that compared with the negative group, the relative mRNA expression level in the siRNA-IL17Amode2 group was 61.0%, and the knockdown effect of siRNA-IL17Amode2 on IL-17 was obvious.

[0074] 4.4 Photos of the mouse back

[0075] The back conditions of the mice were observed and photographed on day 5, day 8, and day 11 of the experiment. Typical back photos of mice in the Secukinumab group, negative group, and siRNA-IL17Amode2 group, as well as HE staining images of back skin sections, are shown in the figure below. Figure 8-9 shown.

[0076] Depend on Figure 8 The results showed that on day 5, the back scales of the mice in the Secukinumab group and the negative group were obvious, the scales of the mice in the siRNA-IL17Amode2 group were fine, and the skin of the three groups of mice was dark red; on day 8, the three groups of mice had obvious scales, and the scales of the mice in the negative group were the most serious, followed by the Secukinumab group, with more scales, and the scales of the siRNA-IL17Amode2 group were slightly lighter than those in the Secukinumab group; on day 11, the back skin of the mice in the siRNA-IL17Amode2 group recovered well, the mouse skin regained elasticity, comparable to the effect of the positive Secukinumab group, and began to show signs of hair growth.

[0077] Depend on Fig. 9 The results showed that compared with the siRNA-IL17A mode2 group, on day 5, the epidermis of the negative group and the Secukinumab group was obviously damaged, and the skin protrusions were elongated; on day 8, the negative group and the Secukinumab group were hyperkeratinized, and a large number of immune cells infiltrated; on day 11, the skin was gradually recovering, but the epidermis of the siRNA-IL17A mode2 group was smoother, the skin thickness was normal, and the number of inflammatory cells decreased.

[0078] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A siRNA for inhibiting IL-17A gene expression, characterized in that: The sequence of the sense strand of the siRNA is SS-5'AGAUAUCCCUCUGUGAUCUGGGA-3', and the sequence of the antisense strand is AS-5'UCCCAGAUCACAGAGGGAUAUCU-3'.

2. The siRNA for inhibiting IL-17A gene expression according to claim 1, characterized in that: The siRNA further comprises chemical modifications to its sense strand and antisense strand.

3. The siRNA for inhibiting IL-17A gene expression according to claim 2, characterized in that: The chemical modification is selected from one or both of methoxy modification and fluorine modification.

4. The siRNA for inhibiting IL-17A gene expression according to claim 3, characterized in that: The chemical modification is to perform methoxy modification on the 4th, 6th to 12th, 14th and 17th to 19th bases of the sense strand from the 5' end and the 8th and 21st bases of the antisense strand from the 5' end.

5. The siRNA for inhibiting IL-17A gene expression according to claim 3, characterized in that: The chemical modification is to perform methoxy modification on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st and 23rd bases of the sense strand from the 5' end and the 1st, 2nd, 4th, 6th, 8th, 10th, 12th, 14th, 16th, 18th, 20th and 22nd bases of the antisense strand from the 5' end; and to perform fluorine modification on the 2nd, 4th, 6th, 8th, 10th, 12th, 14th, 16th, 18th, 20th and 22nd bases of the sense strand from the 5' end and the 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st and 23rd bases of the antisense strand from the 5' end.

6. The siRNA for inhibiting IL-17A gene expression according to claim 4 or 5, characterized in that: The structural formulas of the methoxy-modified and fluorinated bases are shown in the following formulas Ⅰ and Ⅱ, respectively:

7. Use of siRNA in the preparation of a drug for treating psoriasis, characterized in that: The siRNA is the siRNA according to any one of claims 1 to 6.

8. Use of the siRNA according to claim 7 in preparing a drug for treating psoriasis, characterized in that: The drug is administered by skin administration.